A 68-year-old Medicare Part D enrollee with a BMI of 34, hypertension, and no diabetes diagnosis takes her semaglutide (Wegovy) prescription to the pharmacy and is quoted a cash price near $1,000 for a 28-day supply because the claim was rejected. Her neighbor in the same apartment building, prescribed the identical drug after a documented myocardial infarction two years earlier, pays a $45 co-pay under the same Part D plan. Same molecule, same dose, same pharmacy counter — different outcome, because Medicare Part D GLP-1 coverage in 2026 still turns on the diagnosis code attached to the claim, not on the name printed on the box. Understanding that distinction is the difference between a covered prescription and a denied one.
The Statutory Exclusion: Why Part D Was Never Built to Pay for Obesity Drugs
Medicare Part D's drug benefit was built on top of the Medicaid drug exclusion list codified in Social Security Act §1927(d)(2), which Congress carried into the Part D statute at §1860D-2(e)(2)(A). That provision excludes 'agents when used for anorexia, weight loss, or weight gain' from the definition of a covered Part D drug, alongside other historically excluded categories like fertility drugs and cosmetic agents. The exclusion predates the current generation of GLP-1 receptor agonists by decades and was never written with incretin pharmacology in mind.
The practical effect is that a Part D plan is legally barred from paying for semaglutide, tirzepatide, or any GLP-1 agonist when the documented purpose of the prescription is weight loss by itself. This is not plan discretion or a formulary choice — it is a statutory floor that no individual sponsor can override by adding the drug to its formulary. Plans can choose to cover a drug for an approved indication outside the exclusion, but they cannot lawfully reimburse it for obesity alone under current law.
This is the root of nearly every denial letter beneficiaries receive. The workaround that has emerged since 2024 is not a change in the exclusion itself — it is the use of newer FDA approvals that sit outside the weight-loss category entirely, discussed below.
The Comorbidity Workaround: How Wegovy Earned a Cardiovascular Indication
In March 2024, the FDA approved semaglutide (Wegovy) for a second indication: reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight. That approval was grounded in the SELECT trial (NCT03574597, n=17,604), which showed a hazard ratio of 0.80 (95% CI, 0.72–0.90) for the composite MACE endpoint over a median follow-up of 39.8 months.
Because that indication is a cardiovascular risk-reduction claim rather than a weight-loss claim, CMS issued guidance clarifying that Part D plans may cover semaglutide for this specific population without running into the §1860D-2(e)(2)(A) exclusion. The qualifying patient profile is narrow: an adult with obesity or overweight and a documented history of cardiovascular disease — prior MI, stroke, or symptomatic peripheral artery disease are the typical qualifying diagnoses plans look for in prior authorization criteria.
This created the first real crack in the obesity exclusion wall, but it is not a blanket approval. A patient with obesity and no cardiovascular diagnosis still falls outside this pathway, even on the identical drug and dose. The comparative efficacy data on semaglutide relative to other agents in this same drug class, including head-to-head results against liraglutide, is covered in more detail in the STEP 8 head-to-head trial analysis.
Zepbound and Sleep Apnea: The Second Comorbidity Pathway
Tirzepatide followed a parallel route. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA program, which reported apnea-hypopnea index reductions of roughly 25 to 29 events per hour from baseline depending on the trial arm and background positive airway pressure use. That is an independently approved, non-weight-loss indication, which again sits outside the Part D exclusion.
Part D plans that elect to cover Zepbound under this pathway typically require documentation of a qualifying sleep study, a formally diagnosed AHI threshold, and in many cases evidence that the patient has tried or cannot tolerate continuous positive airway pressure therapy. This is step therapy applied to a comorbidity claim, not an obesity claim, and plans vary in how strictly they enforce it.
The same mechanism — GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonism producing substantial weight reduction with downstream effects on upper airway fat deposition — is why tirzepatide performs differently across indications than agents acting on GLP-1 alone. Clinicians weighing the trade-offs between indications and dosing also track safety signals during therapy; the incidence data on gastroparesis with GLP-1 agonists is relevant to monitoring regardless of which indication is on the prior authorization form.
Diabetes Remains the Easy Case: Ozempic, Mounjaro, Rybelsus
The least complicated Part D coverage story in 2026 is still type 2 diabetes. Semaglutide marketed as Ozempic, tirzepatide marketed as Mounjaro, and oral semaglutide marketed as Rybelsus are approved for glycemic control and have never been subject to the weight-loss exclusion, because the underlying indication is diabetes management, not obesity. These drugs appear on the large majority of Part D formularies, generally in a mid-to-upper tier with standard prior authorization or step-therapy criteria tied to an A1C threshold or prior metformin trial.
This creates a documented pattern of off-label-adjacent prescribing pressure: a clinician managing a patient with obesity and prediabetes, or obesity and an A1C just under the diabetes threshold, has a financial incentive to document the diabetes-adjacent diagnosis rather than obesity alone, even when the clinical reasoning for starting therapy is weight-driven. Pharmacy benefit managers have flagged this pattern in claims audits, though enforcement varies by plan sponsor.
Oral formulations complicate this further. Higher-dose oral semaglutide, studied in the OASIS program for weight outcomes rather than glycemic control, faces the same obesity-indication exclusion as the injectable weight-loss formulation, even though the diabetes-indicated oral tablet (Rybelsus) is covered. The distinction between the two uses of the same oral molecule is detailed in the OASIS trial weight-endpoint data, and it is a frequent source of pharmacy-counter confusion for patients who assume an oral pill form automatically carries the same coverage as the injectable diabetes drug.
The November 2024 Proposed Rule and Its Reversal
In November 2024, CMS issued a proposed rule that would have reinterpreted obesity itself as a disease state eligible for Part D and Medicaid coverage, effectively removing the weight-loss exclusion's practical bite for FDA-approved anti-obesity medications. CMS's own actuarial estimates attached to the proposal projected substantial new federal spending over a multi-year budget window, reflecting the scale of the Medicare population that could newly qualify [CITATION NEEDED: exact CMS Office of the Actuary ten-year cost estimate for the November 2024 proposed rule].
The proposal drew significant comment volume from patient advocacy groups supporting expanded access and from fiscal watchdogs citing the cost projections. Before the rule could be finalized, the incoming administration's CMS leadership elected not to proceed with it in its original form, leaving the statutory exclusion in §1860D-2(e)(2)(A) as the operative law into 2026 rather than the reinterpretation CMS had proposed.
The net effect is that the obesity exclusion survived a serious, formally proposed challenge. Coverage expansion since then has continued to arrive piecemeal, indication by indication, rather than through the single broad rule change that was on the table in late 2024. That pattern of incremental, indication-specific coverage is likely to continue as newer agents such as retatrutide and oral candidates complete their own regulatory review, a dynamic also shaping how payers are expected to treat emerging dual and triple agonists like those compared in the CagriSema versus tirzepatide analysis.
The 2026 Demonstration: What the Pilot Actually Covers
Separate from the formal rulemaking process, federal health agencies have moved toward narrower demonstration authority to test obesity-drug coverage within defined populations and budget caps, rather than a permanent statutory fix. Demonstration projects of this kind typically run through the CMS Innovation Center, apply to a limited subset of beneficiaries or states, and carry sunset dates that require renewal or a permanent rule to continue [CITATION NEEDED: specific enrollment scope, eligibility criteria, and price terms of the 2026 Medicare/Medicaid obesity-drug demonstration].
For prescribers and patients, the operational reality is that a demonstration is not the same thing as a formulary change. Eligibility under a pilot is typically narrower than a straightforward Part D benefit, often restricted by diagnosis, geography, or enrollment caps, and beneficiaries outside those parameters remain subject to the standard exclusion and comorbidity pathways described above.
Because pilot terms can change between plan years, the safest practice for both prescribers and beneficiaries is to verify current-year eligibility directly with the Part D sponsor or through Medicare.gov's plan finder rather than relying on prior-year coverage assumptions. This is also where supply-chain and sourcing questions intersect with coverage questions, since patients facing a denial sometimes look toward compounded alternatives; the current legal landscape for that option is addressed in the compounded semaglutide legal status review.
Prior Authorization and Appeals: Reading the Denial Letter
A Part D rejection at the pharmacy counter generates a specific reason code, and distinguishing between them determines the next step. A rejection coded as a formulary exclusion for an anti-obesity indication is a statutory issue that prior authorization paperwork cannot fix. A rejection coded as a prior authorization requirement, by contrast, means the plan believes the drug could be covered if the clinician submits qualifying documentation — the cardiovascular history, the sleep study, or the diabetes diagnosis discussed above.
The standard Part D process after an initial denial is a coverage determination request, which the plan must generally resolve within 72 hours for a standard request or 24 hours for an expedited request. If denied again, the next step is a redetermination, followed by an independent review entity appeal, and ultimately an administrative law judge hearing for claims above the applicable dollar threshold. Each stage requires updated clinical documentation rather than a repeat of the same denied claim.
Common points of failure in this process include submitting a prior authorization request coded only for obesity when a qualifying comorbidity exists in the chart but was never documented in the submission, and missing the deadline window for redetermination requests, which is typically 60 days from the denial notice. Patients and clinics that track these deadlines and resubmit with the correct diagnosis code see materially higher approval rates on appeal than those who resubmit identical paperwork a second time.
A Practical Playbook for Clinicians and Patients in 2026
For a clinic managing Medicare patients on GLP-1 therapy, the operational starting point is a chart review before the prescription is ever sent to the pharmacy: confirm whether the patient has a diabetes diagnosis, a documented cardiovascular event, or a sleep study supporting an OSA diagnosis, and code the encounter accordingly rather than defaulting to an obesity-only problem list. That single step resolves a large share of avoidable denials before they happen.
Where none of those comorbidities exist, the realistic options are a cash-pay arrangement through a manufacturer savings program, a switch to a Medicare Advantage plan with relevant supplemental benefits, or a documented clinical reassessment to determine whether an undiagnosed comorbidity — undiagnosed sleep apnea is a common finding — is in fact present and simply has not been tested for.
- Verify the active FDA-approved indication tied to the prescription before submitting a claim, not after a denial arrives.
- Keep a copy of the qualifying diagnostic evidence — sleep study report, cardiology notes, A1C trend — in the prior authorization packet from the first submission.
- Track the 60-day appeal window from the date on the denial notice, not the date the prescription was filled.
- Reassess plan eligibility each enrollment period, since formulary tiers and prior authorization criteria for GLP-1 drugs have changed from one Part D plan year to the next.
None of this guarantees approval, and plan-level variation remains significant even within the comorbidity pathways described above. The decision to pursue a specific indication-based coverage route, or to consider safety trade-offs such as those reviewed in the FDA and EMA's evaluation of neuropsychiatric signals summarized in the GLP-1 and suicidal ideation regulatory review, belongs with the prescribing clinician working through the individual patient's full risk profile.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.